| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.271.37.22441 |
| P8608 | Fatcat ID | release_r33vghhnrzd4lhrkupoan27czu |
| P698 | PubMed publication ID | 8798408 |
| P5875 | ResearchGate publication ID | 273255248 |
| P50 | author | Marco A. Pierotti | Q30668534 |
| P2093 | author name string | Delia D | |
| Pfahl M | |||
| Fanjul AN | |||
| Rideout D | |||
| Yu JQ | |||
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 22441-22446 | |
| P577 | publication date | 1996-09-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors | |
| P478 | volume | 271 |
| Q40813595 | 4-(N-hydroxyphenyl)retinamide can selectively induce apoptosis in human epidermoid carcinoma cells but not in normal dermal fibroblasts |
| Q40922678 | 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway |
| Q28476770 | A computational approach to finding novel targets for existing drugs |
| Q37798563 | All trans retinoic acid and cancer |
| Q44251894 | Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells |
| Q43645271 | An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies |
| Q58905775 | Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives |
| Q57980420 | Apoptosis of Human Neuroblastoma Cells Induced by Liposome-Encapsulated Fenretinide |
| Q35572432 | Breast cancer prevention trials using retinoids |
| Q28375233 | Characterization of retinoic acid receptor-deficient keratinocytes |
| Q34297476 | Chemoprevention of breast cancer with fenretinide |
| Q33890132 | Chemoprevention of breast cancer: the Italian experience. |
| Q34605217 | Classical and novel retinoids: their targets in cancer therapy |
| Q40042153 | Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro |
| Q41550862 | Complementary roles of retinoic acid and TGF-β1 in coordinated expression of mucosal integrins by T cells |
| Q40380549 | Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells |
| Q28366043 | Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line |
| Q40621336 | Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids |
| Q38524471 | Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers |
| Q36114834 | Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells |
| Q43565315 | Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma |
| Q40794709 | Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis |
| Q40703405 | Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line |
| Q39417242 | Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration |
| Q40781324 | Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model |
| Q35830496 | Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? |
| Q34107940 | Fenretinide and cancer prevention |
| Q44483601 | Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation |
| Q51005071 | Fenretinide prevents obesity in aged female mice in association with increased retinoid and estrogen signaling. |
| Q36635330 | Fenretinide treatment prevents diet-induced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus. |
| Q35570960 | Fenretinide: a prototype cancer prevention drug |
| Q40983620 | Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. |
| Q44615409 | HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production |
| Q28572628 | Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis |
| Q27653437 | Identification and Characterization of a Non-retinoid Ligand for Retinol-binding Protein 4 Which Lowers Serum Retinol-binding Protein 4 Levels in Vivo |
| Q24308824 | Identification of a novel human kinesin-related gene (HK2) by the cDNA differential display technique |
| Q54123342 | Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. |
| Q36573611 | Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids |
| Q28274812 | Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells |
| Q40612715 | Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells |
| Q41093212 | Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells |
| Q78169779 | Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins |
| Q54118877 | Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. |
| Q36293028 | Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. |
| Q40938112 | Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). |
| Q40781320 | N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention |
| Q40619381 | Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells |
| Q36864271 | Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo |
| Q40629920 | Potent Cytotoxic Effects of Novel Retinamide Derivatives in Ovarian Cancer Cells |
| Q28260445 | Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid |
| Q40939844 | Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway |
| Q44791782 | Retinoic acid enhances the gene expression of human polymeric immunoglobulin receptor (pIgR) by TNF-alpha |
| Q41049278 | Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide |
| Q39576499 | Retinoic acid receptor gamma1 (RARgamma1) levels control RARbeta2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. |
| Q35603386 | Retinoid targets for apoptosis induction |
| Q28379199 | Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation |
| Q34002981 | Retinoids and ovarian cancer |
| Q34866703 | Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives |
| Q38418725 | Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor |
| Q41018777 | Selective activation of an apoptotic retinoid precursor in macrophage cell lines |
| Q34580753 | Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention |
| Q33263984 | Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs |
| Q43614269 | Suppression of pRB expression in normal human mammary epithelial cells is associated with resistance to all-trans-retinoic acid but not N-(4-hydroxylphenyl)-retinamide |
| Q43649728 | Synthesis and biological activity of glycosyl conjugates of N-(4-hydroxyphenyl)retinamide. |
| Q36788454 | Synthetic retinoid fenretinide in breast cancer chemoprevention |
| Q24321948 | The Retinoic Acid Receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production |
| Q37947907 | The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. |
| Q53682893 | Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. |
| Q37378329 | Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells |
| Q38362494 | Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxyphenyl)retinamide (4HPR). |
| Q74234874 | pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide |
Search more.